Related Experiment Video
Updated: Apr 24, 2026
09:03
The CYP2D6 Animal Model: How to Induce Autoimmune Hepatitis in Mice
Published on: February 3, 2012
21.6K
Biotherapy for autoimmune liver diseases.
1Beijing You'an Hospital, Capital Medical University, Beijing, 100069, China. duan2517@163.com.
Current Pharmaceutical Biotechnology
|September 13, 2014
Summary
New biotherapies show promise for autoimmune liver diseases unresponsive to standard treatments. Further clinical trials are essential to establish safety and efficacy for these chronic inflammatory conditions.
Area of Science:
- Hepatology and Immunology
Background:
- Autoimmune liver diseases involve immune-mediated attacks on liver cells and bile ducts.
- Current treatments like ursodeoxycholic acid, prednisolone, and azathioprine are not universally effective.
- Refractory cases necessitate novel therapeutic strategies.
Purpose of the Study:
- To provide an overview of emerging biotherapy options for autoimmune liver diseases.
- To highlight the need for further research into biotherapy for refractory autoimmune liver diseases.
Main Methods:
- Literature review of current and emerging biotherapies for autoimmune liver diseases.
- Analysis of the status of biotherapy validation in clinical practice.
Main Results:
- Biotherapy is a rapidly developing field for chronic autoimmune liver diseases.
- No clinically validated standard biotherapy currently exists for these conditions.
Conclusions:
- Emerging biotherapies offer potential for autoimmune liver diseases resistant to conventional therapies.
- Rigorous clinical trials are required to confirm the safety and effectiveness of biotherapies before widespread adoption.
Related Concept Videos
01:29Autoimmune Disorders
2.3K
Autoimmune diseases are a group of disorders in which the body's immune system mistakenly attacks its own cells, tissues, and organs. This results from an overactive immune response against substances and tissues normally present in the body. Let's delve into the concept and mechanism of autoimmune diseases from an immune system point of view, explore different causes and examples of such diseases, and discuss potential solutions.
Concept and Mechanism of Autoimmune Diseases
The immune...
Concept and Mechanism of Autoimmune Diseases
The immune...
2.3K
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
863
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
863
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
739
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
739
01:29Inflammatory Bowel Disease IV: Pharmacological Management
1.1K
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
1.1K
01:22Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test
271
In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess...
271
01:26Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow
377
Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug...
377